Sanofi-Aventis Sa

Latest Sanofi-Aventis Sa Items
  • Early test suggests dengue vaccine possible

    Results from an early test of a dengue vaccine suggest it isn't ideal, but scientists say the study is still encouraging news in the global fight against the disease known as "break-bone fever."


  • Early test suggests dengue vaccine possible

    Results from an early test of a dengue vaccine suggest it isn't ideal, but scientists say the study is still encouraging news in the global fight against the disease known as "break-bone fever."


  • Sanofi-Aventis to buy Genzyme in $20.1 bln deal

    French drug maker Sanofi-Aventis SA has agreed to buy Genzyme Corp. in an all-cash deal that values the U.S. biotechnology company at $20.1 billion.


  • FILE - In this Feb. 11, 2009 file photo, Chris Viehbacher CEO of Sanofi-Aventis SA, gestures while announcing the 2008 full year result in Paris. French drug maker Sanofi-Aventis SA has agreed to buy Genzyme Corp. in a sweetened all-cash deal that values the U.S. biotechnology company at $20.1 billion Wednesday, Feb. 16, 2011, ending months of corporate haggling. (AP Photo/Michel Euler, file)

    Sanofi-Aventis to buy Genzyme for $20.1 bln cash

    French drug maker Sanofi-Aventis SA has agreed to buy Genzyme Corp. in a sweetened all-cash $20.1 billion deal that ends months of corporate haggling and positions Sanofi at the forefront of the market in lucrative drugs for rare genetic disorders.


  • FDA warns of liver damage reports with Sanofi drug

    Federal health officials are warning doctors and patients that a recently-launched heart drug from Sanofi-Aventis SA has been linked to liver damage in a handful of patients.


  • Sanofi-Aventis sticking to first offer for Genzyme

    French drugmaker Sanofi-Aventis SA is sticking to its original offer of $69 a share to buy U.S. biotech company Genzyme Corp., a Sanofi spokesman said Thursday.


  • FDA panel rejects diet drug

    A weight-loss drug that was expected to be a blockbuster failed to gain approval yesterday from a key advisory committee to the Food and Drug Administration because it appears to increase the risk of suicidal tendencies.


Happening Now